- Home
- FTI vs ROIV Comparison
FTI vs ROIV Comparison
Compare FTI & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FTI | ROIV |
|---|---|---|
| Founded | 1884 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | 721 |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.1B | 28.7B |
| IPO Year | 2016 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FTI | ROIV |
|---|---|---|
| Price | $71.22 | $37.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 9 |
| Target Price | ★ $65.50 | $28.94 |
| AVG Volume (30 Days) | 2.5M | ★ 8.5M |
| Earning Date | 04-30-2026 | 05-28-2026 |
| Dividend Yield | ★ 0.26% | N/A |
| EPS Growth | ★ 20.42 | N/A |
| EPS | ★ 1.53 | N/A |
| Revenue | ★ $9,932,600,000.00 | $8,260,000.00 |
| Revenue This Year | $8.49 | N/A |
| Revenue Next Year | $5.53 | $744.61 |
| P/E Ratio | $46.29 | ★ N/A |
| Revenue Growth | ★ 9.35 | N/A |
| 52 Week Low | $35.29 | $14.59 |
| 52 Week High | $80.70 | $42.50 |
Technical Indicators
Market Signals| Indicator | FTI | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 52.54 |
| Support Level | N/A | $33.15 |
| Resistance Level | N/A | $42.50 |
| Average True Range (ATR) | 0.00 | 1.40 |
| MACD | 0.00 | -0.16 |
| Stochastic Oscillator | 0.00 | 53.23 |
Price Performance
Historical ComparisonAbout FTI TechnipFMC plc
TechnipFMC PLC is the key provider of offshore oilfield services, offering integrated deep-water offshore oil and gas development solutions that span the full spectrum of subsea equipment and subsea construction services. The company also provides various pieces of surface equipment used with onshore oil and gas wells. TechnipFMC originated with the 2017 merger of Technip and FMC Technologies. Geographically it operates in Latin America generating the maximum revenue, then Europe and Central Asia, Africa, North America, Asia Pacific and Middle East.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.